Please lik_老虎社区_美港股上老虎

Minz98
2021-11-29

Please like

Merck stock dipped more than 4% in morning trading

Merck stock dipped more than 4% in morning trading as it was downgraded to neutral from buy by Citi

Merck stock dipped more than 4% in morning trading

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

推荐
最新

暂无评论

热议股票

关于我们·老虎社区守则·老虎社区账号管理规范·老虎社区服务协议·老虎社区隐私政策

公司名称：北京至简风宜信息技术有限公司

违法和不良信息投诉：010-5681-3562（工作时间9:30-18:30）

邮箱：service@laohu8.com

营业执照：91110105MA01A4U55R

ICP备：京ICP备18016422号

网安备：京公网安备11010502036490

关注我们

{"i18n":{"language":"zh_CN"},"data":{"magic":2,"id":600722486,"tweetId":"600722486","gmtCreate":1638199304062,"gmtModify":1638199304150,"author":{"id":3582803159303555,"authorId":3582803159303555,"authorIdStr":"3582803159303555","name":"Minz98","avatar":"https://static.tigerbbs.com/2d2093834aabec0c8de1bff4779af70e","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Please like&nbsp;</p></body></html>","htmlText":"<html><head></head><body><p>Please like&nbsp;</p></body></html>","text":"Please like","highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":2,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/600722486","repostId":1137393357,"repostType":4,"repost":{"id":"1137393357","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1638197348,"share":"https://www.laohu8.com/m/news/1137393357?lang=&edition=full","pubTime":"2021-11-29 22:49","market":"us","language":"en","title":"Merck stock dipped more than 4% in morning trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1137393357","media":"Tiger Newspress","summary":"Merck stock dipped more than 4% in morning trading as it was downgraded to neutral from buy by Citi ","content":"<p>Merck stock dipped more than 4% in morning trading&nbsp;as&nbsp;it&nbsp;was downgraded to neutral from buy by Citi Research.</p>\n<p><img src=\"https://static.tigerbbs.com/921cc70c00deb0f565b98bc2a7218479\" tg-width=\"840\" tg-height=\"470\" referrerpolicy=\"no-referrer\"></p>\n<p>Disappointing results for some major drugs has limited the upside for&nbsp;Merck’s stock, according to Citi.</p>\n<p>Analyst Andrew Baum downgraded Merck to neutral from buy, saying in a note to clients on Monday that development struggles for the company’s HIV drug islatravir was taking a bite out of Merck’s long-term potential.</p>\n<p>“Our long-standing investment thesis on MRK was based on underappreciation of MRK’s pipeline, especially islatravir for HIV to help to offset the forthcoming Keytruda [loss of exclusivity] ... We have removed our $4bn risk adjusted 2030 estimate from our model, reducing our EPS estimates up to 10%,” the note said.</p>\n<p>Citi cut its price target on Merck to $85 per share from $105. The new target is about 7% above where the stock closed on Friday.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Merck stock dipped more than 4% in morning trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMerck stock dipped more than 4% in morning trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-11-29 22:49</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Merck stock dipped more than 4% in morning trading&nbsp;as&nbsp;it&nbsp;was downgraded to neutral from buy by Citi Research.</p>\n<p><img src=\"https://static.tigerbbs.com/921cc70c00deb0f565b98bc2a7218479\" tg-width=\"840\" tg-height=\"470\" referrerpolicy=\"no-referrer\"></p>\n<p>Disappointing results for some major drugs has limited the upside for&nbsp;Merck’s stock, according to Citi.</p>\n<p>Analyst Andrew Baum downgraded Merck to neutral from buy, saying in a note to clients on Monday that development struggles for the company’s HIV drug islatravir was taking a bite out of Merck’s long-term potential.</p>\n<p>“Our long-standing investment thesis on MRK was based on underappreciation of MRK’s pipeline, especially islatravir for HIV to help to offset the forthcoming Keytruda [loss of exclusivity] ... We have removed our $4bn risk adjusted 2030 estimate from our model, reducing our EPS estimates up to 10%,” the note said.</p>\n<p>Citi cut its price target on Merck to $85 per share from $105. The new target is about 7% above where the stock closed on Friday.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRK":"默沙东"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1137393357","content_text":"Merck stock dipped more than 4% in morning trading as it was downgraded to neutral from buy by Citi Research.\n\nDisappointing results for some major drugs has limited the upside for Merck’s stock, according to Citi.\nAnalyst Andrew Baum downgraded Merck to neutral from buy, saying in a note to clients on Monday that development struggles for the company’s HIV drug islatravir was taking a bite out of Merck’s long-term potential.\n“Our long-standing investment thesis on MRK was based on underappreciation of MRK’s pipeline, especially islatravir for HIV to help to offset the forthcoming Keytruda [loss of exclusivity] ... We have removed our $4bn risk adjusted 2030 estimate from our model, reducing our EPS estimates up to 10%,” the note said.\nCiti cut its price target on Merck to $85 per share from $105. The new target is about 7% above where the stock closed on Friday.","news_type":1},"isVote":1,"tweetType":1,"viewCount":820,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":10,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"hasMoreComment":false,"orderType":2}

Merck stock dipped more than 4% in morning trading

评论（2）

热议股票